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Background: The purpose of this exploratory study was threefold, ie, to clarify the unique 
psychosocial challenges facing those living with systemic lupus erythematosus (SLE), to 
distinguish which sociodemographic variables impact the lives of SLE patients, and generate 
knowledge regarding the way patients perceive SLE medication regimens.
Methods: This was a cross-sectional exploratory study in 378 patients diagnosed with SLE 
and receiving services from the SLE Lupus Foundation in New York City. In addition to socio-
demographic variables, the instrument used consisted of two scales, ie, the Systemic Lupus 
Erythematosus Needs Questionnaire (SLENQ) and the Multidimensional Health Locus of 
Control Scale, as well as questions regarding subjective perceptions of side effects from SLE 
medication.
Results: The highest general cause of self-reported depressive and anxious feelings was changes 
in appearance due to SLE, and limitations in physical abilities due to SLE (primarily from muscle 
and joint pain). The higher the sense of control over SLE, the less likely respondents were to 
report feeling depressed and anxious. African-American and Hispanic SLE patients reported a 
higher level of unmet psychological needs due to SLE than did their other ethnic counterparts. 
Weight gain and hair loss were the most likely medication side effects and also the most likely 
causes of SLE-related depression and anxiety.
Conclusion: Those living with SLE are at risk for feelings of depression and anxiety. 
  African-American and Hispanic women are at higher risk for these emotional states. 
  Comprehensive assessment across the disciplines should screen this group of patients for depres-
sion and anxiety, and be prepared to refer them to patient education and social work counseling 
as indicated.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with acute 
periodic flare-ups of symptoms impacting any organ system and resulting in poten-
tially life-threatening complications.1,2 Some of the significant complications of 
treatment include hirsutism, weight gain, osteoporosis, osteonecrosis, accelerated 
atherosclerosis, and retinal damage.3,4 These side effects and complications can lead 
to significant functional and emotional challenges. Patients often experience a high 
degree of psychological symptoms, including anxiety, depression, mood disorders, 
and decreased health-related quality of life.5–8 This article reports on the findings from 
a preliminary exploratory study on how patients living with SLE perceive their SLE-
related   challenges. This was a hypothesis-generating study to tease out some of the 
nuances of the psychosocial challenges for this population.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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While there are various empirical studies across the health 
care disciplines on the psychosocial impact of SLE illness, 
these studies identified general psychosocial experiences 
without identifying some of the more complex emotional 
needs of those living with SLE in the US.8–11 This study 
included several instruments, including one that had only 
been used once previously, ie, the Systemic Lupus Erythe-
matosus Needs Questionnaire (SLENQ) and another known 
as the Multidimensional Health Locus of Control, that had 
not ever been used with the SLE population previously. 
There are many biopsychosocial implications of SLE that 
have been shown to precipitate depression and anxiety. The 
disease itself, unexpected exacerbations, medical regimen 
side effects, and medical care issues are often identified as 
the sources of depressed feelings.14–18 One complex nuance, 
that has not been addressed fully, is how much does disease 
activity influence emotional states such as depression and 
anxiety? And which disease manifestations create the most 
emotional distress? A patient being treated for disease activity 
will have medical and nursing needs, and will likely have 
needs for occupational and physical therapy, as well as social 
work counseling.8–11 The disease disproportionally impacts 
women (9:1), and women will experience physical changes, 
such as rashes or a cushingoid appearance, which can trig-
ger feelings of low self-esteem, depression, and anxiety at 
significantly higher rates than those of healthy women.12–20
Danoff-Burg and Friedberg studied the unmet needs of 
112 SLE patients. Key findings regarding the impact of SLE 
included tiredness (94%), need for assistance about feeling 
anxious or depressed (78% and 71%, respectively), and 
nearly half (48%) desired assistance “related to maintaining 
relationships with friends”.5 These findings are consistent 
with similar international research on the psychosocial 
impact of SLE.11
Moses et al developed and used an SLENQ specifically 
for 386 SLE patients from a support association in Australia 
to ascertain their unmet psychosocial needs.12 Five of the 
highest levels of unmet needs were in the psychological 
domain. They found that “need for help with psychosocial 
and lifestyle problems outranked the needs for information”.12 
A key implication from this study was that SLE patients 
should be assessed early on for the likelihood of depressive 
sequelae.
The current range of multidisciplinary literature indicates 
that SLE patients have a high vulnerability for self-reported 
feelings of depression and anxiety.15–19 It is unclear which 
SLE manifestations contribute to the forms of psychosocial 
distress occurring most often, which sociodemographic 
cohorts may be at higher risk for such psychosocial   distresses, 
and the nature of the physical and emotional sequelae 
of SLE medication regimens. We therefore performed a 
cross-sectional study of 378 SLE patients to identify these 
psychosocial experiences and which ethnicities may be at 
risk for which psychosocial stressors.
Materials and methods
Participants and procedures
All 899 individuals in the New York SLE Lupus Founda-
tion contact database were sent the survey instrument. All 
patients had self-reported having SLE. To protect anonymity, 
chart reviews were not part of the exploratory process. Each 
respondent received a six-page survey to investigate their 
psychosocial experiences of living with SLE. The survey 
instrument was written at an eighth-grade reading level and 
was also available in Spanish. The survey was completely 
anonymous and deidentified. An informed consent letter was 
sent along with each survey that explained the purpose of the 
study, its voluntary nature, that participants could discontinue 
without any penalty, and that the information would be used 
in the aggregate with no identifying information. To maintain 
the anonymity of patients’ responses, survey completion was 
used instead of a signature on the informed consent letter. 
Packets were distributed to home mailing addresses with 
stamped envelopes, so that completed surveys could be bulk-
mailed to the researchers at Yeshiva University with complete 
anonymity. Of the 899 questionnaires originally distributed, 
19 were returned unopened due to a change of address. Of 880 
received, a total of 378 individuals responded to the survey 
in English or Spanish (336 in English and 42 in Spanish), 
with an overall return rate of 42.9%.
instrument
The survey instrument comprised four components. Part one 
included sociodemographic variables including gender, race, 
and age, as well as time of diagnosis, length of diagnosis, 
education, employment, and relationship status.
Part two consisted of two scales, ie, the SLENQ, devel-
oped and validated by Moses et al,12 which uses a 5-point Lik-
ert scale (1 = no need, 3 = moderate need, 5 = high need) for 
12 different psychosocial factors. For example, the SLENQ 
asks: “How much assistance do you need with your change 
in appearance due to SLE?” and “How much assistance do 
you need because you have anxiety about SLE”.12 For the 
purpose of analysis, three subscales were created from the 
psychosocial need items, ie, depression, anxiety, and socio-
economic coping. Depression was assessed by the following Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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items: feeling depressed due to limitations caused by SLE; 
feeling depressed because of changes in the body; and feeling 
depressed because of side effects. Anxiety regarding SLE 
was assessed by the following items: feeling confused about 
why this disease happened to you; anxiety about changes 
in your appearance; feeling angry about having SLE; feel-
ing uncertain about the future; dealing with anxiety about 
SLE; and anxiety about side effects. Socioeconomic coping 
consisted of the following items: concerns about gaining 
employment; satisfactory performance in job; and coping 
with extra costs. The SLENQ subscales have been validated, 
with higher scores reflecting higher need.11   Reliability of 
the subscales was high, with coefficent alphas of 0.91 for 
depression, 0.90 for anxiety, and 0.76 for economic coping. 
One-way analysis of variance was utilized to test how vari-
ous factors like age, educational level, employment, and race 
impact psychosocial need.
In part three, the second scale was used, ie, the Multi-
dimensional Health Locus of Control Scale measuring the 
respondents’ subjective perceptions of how much control 
they had over their SLE.21 Two subscales, ie, “chance” and 
“internal”, were utilized in this research. Chance refers to the 
mindset that the course of one’s illness is out of one’s control. 
Internal refers to the opposite perspective, ie, “If I manage 
my illness with diet, exercise, compliance with medication 
regimens, I can control its course”. Each is a six-item self-
report questionnaire that uses a 6-point Likert scale, with 
items ranging from 1 (disagree very much) to 6 (agree very 
much). Examples of items included in the chance subscale 
are: “No matter what I do, I am going to get sick”, and “Most 
things that affect my health happen to me by accident”. 
Examples of items included in the internal subscale are: 
“If I get sick, it is my own behavior which determines how 
soon I get well again” and “I am in control of my health”. 
It is important to note that the subscales are independent of 
each other. The internal reliability for these subscales was 
good, with a coefficent alpha of 0.76 for chance and 0.77 for 
internal. Each subscale can range between 1 (lowest need) 
and 6 (highest need).
Part four concluded with open-ended questions about the 
range of medication regimens, side effects, and psychosocial 
impact of those medication regimens.
statistical analysis
The data were analyzed using SPSS (v 17.0; SPSS, Inc, 
Chicago, IL) and STATA (v 11.0; Stata Corp, College 
  Station, TX). Statistical tests used in this analysis included 
the Chi-square, t-test, and analysis of variance. Ordinary least 
squares regression was used to analyze the Likert scale 
  questions on the SLENQ and Multidimensional Health Locus 
of Control scales. Ordinary least squares regression was 
used to perform a multivariate analysis in order to evaluate 
how the different variables affected the outcome measures 
of depression, anxiety, and socioeconomic coping derived 
from the SLENQ. The indicators “internal” and “chance” 
were entered as continuous variables. African-American, 
Hispanic, and Asian were contrasted with White; education 
was coded as some college, college, and advanced degree, 
and contrasted with high school or less education. How the 
respondents rated their experience with SLE was also coded 
as chronic symptoms and frequent flares, and contrasted with 
infrequent flares. Finally, insurance was coded as Medicaid, 
Medicare, and no insurance, and contrasted with private 
insurance. “Coef ” in Table 2 indicates the slope which shows 
how much the degree of an outcome variable (depression, 
anxiety, or socioeconomic coping) changes for every point 
increase in a covariate (chance, internal). For example, when 
“chance” increases by 1, a respondent’s level of depression 
increases by 0.17 points. A respondent who had a score of 5 
on this scale would have a 0.85-point increase (5 × 0.17) in 
their degree of depression. Postestimation Wald tests were 
utilized to test the significance of indicator variables, such 
as race and insurance. With regards to missing data, some 
respondents did not respond to every question, so some items 
were tabulated with less than the total number of respondents. 
List-wise removal of missing data was utilized because 
  missing cases were not missing at random.
Each of the subscales on the SLENQ, ie, depression, 
anxiety, and socioeconomic coping, ranges from 1 (no need) 
to 5 (high need). It has been reported that “… formal statisti-
cal tests for normality are especially undesirable as they will 
have low power in the small samples where the distribution 
matters and high power only in large samples where the 
distribution is unimportant”.22 Given the relatively large 
sample size of nearly 400 subjects reported here, the means 
and the medians were compared for overall skew. When the 
mean and median are equal, it indicates that the distribution 
is symmetrical. The criterion of symmetry is met for each 
scale. Parametric tests perform well with large samples (more 
than 100) even when the data are non-normal.23 As a result, 
the t-test and one-way analysis of variance were utilized to 
compare groups of respondents. The criterion for statistical 
significance in this study was an alpha level of 0.05.
Regarding ordinary least squares regression analysis, each 
of the regression models was tested for normality of residu-
als, homoscedasticity, multicollinearity, model   specification, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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and linearity. The residuals in all three   models deviated 
slightly from normality. Lumley et al point out that “… linear 
regression does not require any assumption of normal dis-
tribution in sufficiently large samples. Previous simulations 
studies show that ‘sufficiently large’ is often fewer than 
100 …”.22 The Breusch–Pagan test for   heteroskedasticity was 
conducted for the models. The results were nonsignificant, 
indicating homogeneity of their respective residuals. The 
variance inflation factor was calculated to test for the presence 
of collinearity in each model. All models had mean variance 
inflation factors close to 1, and no independent variable had a 
variance inflation factor above 2, indicating that the indepen-
dence assumption was met. The models were tested for model 
specification errors, which can inflate regression coefficents. 
This type of error occurs when a relevant variable is omitted 
or an irrelevant one is included. The Ramsey RESET Test was 
utilized to test for this type of error. The results indicated that 
the coefficents in each of the models were not influenced by 
a model specification error. Finally, by utilizing scattergrams 
between the outcome variables and key independent variables, 
the models met the linearity assumption.
Results
sample characteristics
As expected, the vast majority of respondents (n = 357, 
96.5%) were women. Age ranged from 20 to over 67 years, 
with approximately one-third under 35 years (n = 97, 26%), 
one-third aged 36–45 years (n = 100, 27%), and one-third 
aged $46 years (n = 123, 33%). The majority of respondents 
were non-White women, with 40% (n = 144) identifying 
themselves as African-American and 38% (n = 135) as 
  Hispanic. A large majority of the group was either unem-
ployed (19.4%) or receiving disability due to SLE (44%). 
Most of the respondents (70.4%) had been diagnosed with 
SLE more than 5 years earlier and, in the last 12 months, 
more than one-third (37.3%, n = 139) had been hospitalized 
because of complications from SLE. The most frequent 
type of medical coverage for the   respondents was Medicaid 
(44.7%, n = 168), followed by private coverage (29.1%). The 
primary source of medical care for the majority of respon-
dents was provided by a private physician (53.95%, n = 191) 
followed by clinics (37.9%, n = 134). Further demographic 
and socioeconomic data are listed in Table 1. The sociode-
mographic variables of this sample were representative of 
the national profile of this population regarding age, race, 
and ethnicity.19 The only significant divergence was for 
  education. This sample had a higher level of education than 
what is reported in most lupus studies.6–11
Two hundred and twenty-eight (60.58%) respondents 
indicated that their SLE was marked by a chronic set of 
symptoms. Another 16.23% (n = 61) had frequent flares, 
while 19.13% (n = 72) reported infrequent flares. Joint aches, 
fatigue, and muscle pain were present for at least two-thirds 
of the respondents. Respondents reporting chronic symp-
toms or frequent flares had higher psychosocial needs as 
determined by their mean scores, ie, depression (3.8 ± 1.1, 
P = 0.000), anxiety (3.7 ± 1.1, P = 0.000), and socioeconomic 
coping (3.3 ± 1.2, P = 0.043), as compared with those hav-
ing infrequent flares. The level of detail was fairly broad. 
Specific disease manifestations, such as retinal damage and 
renal damage, did not emerge.
sLe needs questionnaire
Participants responded concerning their level of psychosocial 
needs using the SLENQ, as previously detailed. Figure 1 dis-
plays the median scores for each factor from lowest to highest 
need for psychosocial support or assistance. Needing some 
form of psychosocial assistance for coping with their feelings 
Table  1  Demographics  of  a  sample  with  systemic  lupus 
erythematosus (n = 378)
% n
gender
  Male 3.5 13
  Female  96.5 367
race/ethnicity
  Hispanic 37.7 135
  African-American 40.2 144
  Asian 4.7 17
  White 17.3 62
Age (year)
  ,21 3.2 12
  21–35 26.1 97
  36–45 26.9 100
  46–60 33.1 123
  $61 10.8 40
education level
  High school or less 27.4 102
  some college 33.9 126
  college graduate 29 108
  Advanced degree 9.7 36
employment
  Part time 12.2 44
  Full time 24.4 88
  Unemployed 19.4 70
  On disability 44 159
insurance
  Medicaid 44.7 155
  Medicare 17.9 62
  Private insurance 29.1 101
  none 8.4 29Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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of “depression because of changes in body” and “changes in 
appearance” was rated as their highest concern.
Each of the subscales, ie, depression, anxiety, and 
socioeconomic coping, ranged from 1 (no need) to 5 (high 
need). The scales had the following overall means and 
medians: depression mean = 3.5 ± 1.3, median = 3.7, inter-
quartile range = 2; anxiety mean = 3.3 ± 1.2, median = 3.3, 
interquartile range = 2; and socioeconomic coping 
mean = 2.9 ± 1.3, median = 2.7, interquartile range = 2.3. 
The means and medians indicate that respondents had the 
most difficulty coping with depression, followed by anxiety 
and socioeconomic coping. Lumley et al point out that 
respondents reporting chronic symptoms or frequent flares 
are more likely to have higher psychosocial needs with their 
depression, anxiety, and socioeconomic coping, as compared 
with those having infrequent flares.22 Those who reported 
frequent flares had a mean score of 3.8 ± 1.1 for depression 
(P = 0.000), a mean of 3.7 ± 1.1 for anxiety (P = 0.000), 
and a mean of 3.3 ± 1.2 (P = 0.043). Respondents reporting 
chronic symptoms also reported significantly higher psycho-
social needs on depression and anxiety compared with those 
reporting infrequent symptoms. The means were 3.6 ± 1.2 
and 3.4 ± 1.2, respectively.
Education impacts the level of perceived psychosocial 
need, mediating levels of self-reported depression and anxi-
ety associated with SLE. For depression, respondents with 
a high school education or lower rated their psychosocial 
need as 4.0 ± 1.1 compared with those who obtained col-
lege or advanced degrees (3.2 ± 1.3 and 3.0 ± 1.5, respec-
tively, P , 0.001). A similar pattern existed for anxiety, 
where respondents with high school education or less had 
an average need of 3.8 ± 1.2 compared with 3.0 ± 1.2 for 
respondents who had obtained at least a college degree 
(P = 0.001).
Respondents who were unemployed or receiving dis-
ability insurance had higher psychosocial needs on all three 
subscales. Those who were more fully employed reported 
less distress with depression, anxiety, and socioeconomic 
coping. For depression, respondents on disability rated their 
need as 3.8 ± 1.2 compared with 3.1 ± 1.4 and 3.1 ± 1.3 for 
those working part time or full time (P , 0.001). A similar 
pattern was true for anxiety, where respondents receiving 
disability had a mean of 3.6 ± 1.2 compared with 3.0 ± 1.2 
and 3.1 ± 1.2 for respondents working full time and part time, 
respectively (P = 0.001).
Hispanic respondents demonstrated the highest need 
for psychosocial assistance on all three subscales. For 
feelings of depression, Hispanic respondents rated their 
need for assistance as 3.8 ± 1.2 compared with 3.5 ± 3.5 
for African-Americans, 2.9 ± 1.3 for Asians, and 3.2 ± 1.4 
for White respondents (P = 0.009). On anxiety, Hispanic 
respondents rated their need for psychosocial assistance as 
3.5 ± 1.2 compared with 2.8 ± 1.1 for Asians, 3.3 ± 1.2 for 
African-Americans and 3.0 ± 1.2 for Whites (P = 0.013). For 
socioeconomic coping, White respondents displayed little 
need for assistance, with a mean of 2.3 ± 2.3 compared with 
3.1 ± 1.3 for Hispanics, 2.9 ± 1.3 for African-Americans, and 
3.0 ± 1.0 for Asians. Respondents on Medicaid rated their 
psychosocial needs highest on the depression and anxiety 
subscales. Those who indicated a lack of insurance rated 
the highest need for assistance with socioeconomic coping. 
The mean on the depression subscale for Medicaid recipi-
ents was 3.9 ± 1.2 compared with 3.2 ± 1.2 for those who 
utilized private insurance (P , 0.001). Medicaid recipients 
rated the anxiety subscale highest, with a mean of 3.6 ± 1.1 
compared with a mean of 3.1 ± 1.3 for Medicare beneficiaries 
(P = 0.006). Respondents without insurance had the high-
est need for assistance with socioeconomic coping, with a 
mean of 3.6 ± 1.2 as compared with a mean of 2.5 ± 1.3 for 
Medicare recipients, 3.2 ± 1.3 for Medicaid recipients, and 
2.6 ± 1.2 for those receiving private insurance (P = 0.0001). 
The scales had the overall means of 3.5 ± 1.3 for depres-
sion, 3.3 ± 1.2 for anxiety, and 2.9 ± 1.3 for socioeconomic 
  coping. These means indicate that respondents had the most 
difficulty coping with depression, followed by anxiety and 
socioeconomic coping.
The analyses of SLE manifestations revealed that 
those with muscle pain and hair loss were the most likely 
to report feelings of   SLE-related depression and anxiety. 
  Respondents   reporting muscle pain had a mean score of 
changes in appearance
anxiety about SLE
uncertain about the future
depressed/changes in my body
feeling depressed/limitations
anxiety about side effects
angry about having SLE
depressed/side effects
coping with extra costs
job performance
gaining employment
confused why this disease happened
01234
Median 1 = lowest   5 = highest
1.0
3.0
3.0
3.0
3.0
3.0
3.0
4.0
4.0
4.0
4.0
4.0
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3.8 ± 1.2 for depression   compared with 2.9 ± 1.3 for those 
who did not (P , 0.001). The respondents experiencing 
muscle pain also had higher levels of anxiety with a mean 
of 3.7 ± 1.1 compared with 2.8 ± 1.1 for those who were 
not experiencing pain (P , 0.001). Those who experienced 
hair loss had a higher level of depression, with a mean 
of 3.9 ± 1.2 compared with 3.1 ± 1.3 for those who did 
not experience this side effect (P = 0.000). Respondents 
reporting chronic symptoms or frequent flares were more 
likely to have higher psychosocial needs with their depres-
sion, anxiety, and socioeconomic   coping, as compared 
with those having infrequent flares. Those who reported 
frequent flares tested higher for depression, with a mean of 
3.8 ± 1.1 (P = 0.0000) and higher for anxiety, with a mean 
of 3.7 ± 1.1 (P = 0.000).
Those who experienced hair loss also had higher levels 
of anxiety, with a mean of 3.6 ± 1.2 compared with 3.0 ± 1.2 
for those who did not experience this side effect (P = 0.000). 
Similarly, those with muscle pain had higher levels of socio-
economic need, with a mean of 3.0 ± 1.3 compared with 
2.6 ± 1.3 for those who did not (P = 0.006).
Multidimensional health locus  
of control scale findings
The more respondents perceived they had some control over 
the illness, the less likely they were to report high levels of 
depression or anxiety. The mean and median scores for the 
chance and internal subscales on the Multidimensional Health 
Locus of Control Scale were: mean 2.84 ± 1.2, median 2.7, 
interquartile range 1.5, and mean 2.98 ±1.2, median 3.0, 
interquartile range = 1.6, respectively, across all patients. 
Respondents who reported their SLE as having mostly infre-
quent flares (mean 2.5 ± 1.2) perceived that they had more 
control over their health compared with those with chronic 
symptoms (mean 2.9 ± 1.2) or infrequent flares (2.8 ± 0.98, 
P = 0.002).
In Table 2, the column labeled “Coef  ” is the slope. This 
indicates how much the degree of an outcome variable 
(depression, anxiety, and socioeconomic coping) changes for 
every point increase in a covariate (eg, chance, internal). The 
critical locus of control finding was that the more control a 
patient felt they had over their disease, the less likely they 
were to report feelings of depression and anxiety, with the 
specific variances detailed in Table 2.
Depression
The most significant locus of control finding was that for 
those who reported the sensation of having no control 
over their disease; “chance” (Coef = 0.169, P = 0.007) 
were positively associated with more chronic symptoms 
(Coef = 0.648, P = 0.001), frequent flares (Coef = 0.796, 
P = 0.001) and depression (Coef = −0.648, P = 0.001). 
A   college degree (Coef = −0.561, P = 0.010) or advanced 
degree (Coef = −0.644, P = 0.026) compared with a high 
school degree or less was associated with requiring less assis-
tance with depression, as was the case with having   Medicare 
as compared with having private insurance,   Medicaid 
patients required more assistance than those with   insurance. 
Table 2 Ordinary least squares regression for three outcome variables
Dependent 
variable
Depression Anxiety Socioeconomic coping
R2 = 0.29, f = 6.4, P = 0.00 R2 = 0.26, f = 5.7, P = 0.00 R2 = 0.15, f = 2.8, P = 0.00
Independent 
variable
Coef. t 2-tail 
significance
Coef. t 2-tail 
significance
Coef. t 2-tail 
significance
internal −0.071 −10.16 0.247 −0.019 −00.32 0.749 0.005 00.07 0.941
chance 0.111 10.87 0.063 0.138 20.36 0.019 0.051 0.73 0.466
Hispanic −0.089 −0.40 0.687 0.036 0.17 0.867 0.490 10.86 0.064
African-American −0.043 −0.22 0.828 0.182 0.92 0.356 0.488 20.06 0.041
Asian −0.198 −0.61 0.540 −0.191 −0.60 0.549 0.643 10.67 0.095
chronic symptoms 0.483 20.65 0.008 0.334 10.87 0.063 0.264 10.22 0.223
Frequent flares 0.665 20.90 0.004 0.686 30.04 0.003 0.544 20.00 0.047
some college −0.276 −10.47 0.144 −0.101 −0.55 0.585 0.3422 10.53 0.127
college graduate −0.440 −20.14 0.034 −0.404 −20.00 0.047 0.101 00.41 0.680
Advanced degree −0.543 −10.93 0.054 −0.157 −0.57 0.568 0.204 00.61 0.541
Medicaid 0.048 00.27 0.790 −0.075 −00.42 0.675 0.167 0.79 0.431
Medicare −0.589 −20.86 0.005 −0.4831 −20.39 0.017 −0.293 −10.19 0.235
no insurance −0.088 00.33 0.745 0.377 10.42 0.156 10.09 30.42 0.001
Muscle pain 0.507 30.30 0.001 0.671 40.4 0.000 0.381 20.09 0.038
Hair loss 0.555 30.81 0.000 0.341 20.4 0.018 0.099 0.58 0.565Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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The results of the postestimation test   indicated that, compared 
with Medicaid recipients, respondents receiving Medicare 
had a decreased need for psychosocial assistance with 
  depression (−0.589, P = 0.008).
Anxiety
The following covariates significantly increased the need 
for psychosocial assistance for feelings of anxiety: chance 
(Coef = 0.138, P = 0.019) and frequent flares (Coef = 0.686, 
P = 0.003) as compared with infrequent flares, and the 
following covariates decreased the degree of need for psy-
chosocial assistance for feelings of anxiety: college degree 
(Coef = −0.538, P = 0.011) compared with high school. The 
results of the postestimation test indicated that compared with 
respondents with no health insurance, respondents receiving 
Medicare had a decrease in need for psychosocial assistance 
for feelings of anxiety (Coef = 0.483, P = 0.039).
socioeconomic coping
Being African-American (Coef = 0.488, P = 0.041), having 
muscle pain (Coef = 0.380, P = 0.038) and having no insur-
ance (Coef = 1.09, P = 0.001) all significantly increased the 
need for psychosocial assistance for socioeconomic needs. 
The results of postestimation indicated that, compared with 
respondents with no health insurance, respondents receiving 
Medicare had a statistically significant decrease in the need 
for assistance with economic coping (P = 0.034).
Medication result
In analyzing the medication regimens and side effects, it 
is important to note that respondents could and often did 
report use of various combinations of drugs. Because the side 
effects can be a result from any one medication, a combina-
tion of SLE medications, or indeed a disease manifestation, 
the significance of their responses is biased. Because most 
patients were taking more than one medication at a time, 
it is difficult to ascertain which specific medications gave 
rise to which side effects Nevertheless, their perceptions of 
medication side effects is significant because they may have 
misinterpreted side effects incorrectly, and may have titrated 
their own medication regimens based on erroneous percep-
tions and beliefs. It is also important to glean which side 
effects are experienced as being the most distressing to these 
patients, so that treating physicians can assess these issues 
as they develop or adjust treatment plans. At least one-third 
of the respondents used hydroxychloroquine, azathioprine, 
vitamins, methotrexate, steroids, or anti-inflammatory medi-
cations. There are many expected and some unexpected side 
effects of SLE medications that present a myriad of physical 
and emotional challenges. Most respondents experienced 
either hair loss (51.1%) or weight gain (32.7%) as side 
effects from the use of their respective medications. Table 3 
displays the relationship between medications for SLE and 
the types of side effects respondents experienced from them. 
Those utilizing hydroxychloroquine and steroids experienced 
the most side effects. Over two-thirds of those who experi-
enced hair loss (66.4%) or weight gain (67.4%) were taking 
hydroxychloroquine (P = 0.02).
Another set of interesting findings involved respondents’ 
perceptions of the advantages of SLE medications, as 
well as their respective emotional preferences for medica-
tion treatment plans. The chief reported benefit of these 
Table 3 Type of drug by side effects
If you had side effects which is most troubling
Hair loss Weight gain Mood swings Nausea
n % n % n % n %
Hydroxychloroquine Yes 97 66.4% 62 67.4% 13 39.4% 4 44.4%
no 49 33.6% 30 32.6% 20 60.6% 5 55.6%
nsAiD Yes 63 21.4% 47 25.5% 12 17.6% 3 16.7%
no 231 78.6% 137 74.5% 356 82.4% 15 83.3%
steroid Yes 73 49.7% 57 62.0% 16 47.1% 3 33.3%
no 74 50.3% 35 38.0% 18 52.9% 6 66.7%
Methotrexate Yes 19 12.9% 10 10.9% 1 2.9% 1 11.1%
no 128 87.1% 82 89.1% 33 97.1% 8 88.9%
Azathioprine Yes 14 9.5% 13 14.1% 2 5.9% 1 11.1%
no 133 90.5% 79 85.9% 32 94.1% 8 88.9%
cyclosporine Yes 1 0.07% 3 3.3% 1 2.9% 0 0%
no 146 99.3% 89 96.7% 33 97.1% 9 100.0%
Vitamins Yes 75 51.0% 51 55.4% 15 44.1% 2 22.2%
no 72 49.0% 41 44.6% 19 55.9% 7 77.8%
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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medications was the reduction in frequency and intensity 
of flares. When respondents were queried about what they 
would desire from a new medication for SLE, a majority 
(55%, n = 207) desired fewer flares and almost one-third 
(32%, n = 120) desired fewer side effects. Although most 
respondents experienced side effects of hair loss or weight 
gain from their medications, they still expressed that their 
primary desire from a new medication was fewer flares. 
Almost two-thirds (62.4%) of those who experienced hair 
loss desired fewer flares (P = 0.01) in a new medication, 
and 44% who experienced weight gain also desired fewer 
flares (P = 0.01).
Discussion
Because this was an exploratory study with a broad focus, 
it has several inherent limitations and biases. Chief among 
these is the lack of confirmatory American College of 
Rheumatology diagnoses. Nevertheless, these were patients 
who reported themselves as being SLE patients, and were 
being treated for SLE by rheumatologists. The second 
critical limitation is that the majority of this sample was on 
various combinations of SLE medications, and therefore it 
is difficult to discern which side effects were the results of 
which treatments. This study highlighted several complex 
psychosocial reactions that are associated with SLE. Some 
specific correlations between these factors were uncovered 
in this cohort. This study reveals an association between 
chronic symptoms and the likelihood of higher reports of 
depression and anxiety, but not specifically the cause and 
dynamic effect. This may be a bidirectional association, in 
which chronic disease activity influences emotional states 
or, in fact, that feelings of depression and anxiety triggers 
more disease activity.
The sequelae of SLE that may predict higher vulnerability 
for a depressive reaction include more reports of depression 
attributed to changes in appearance (particularly hair loss 
and weight gain) and limitations due to SLE (particularly 
due to muscle pain and joint pain) as was found by Moses12 
in Australia, Shorthall et al24 in England, and Dobkin et al.25 
This finding was also consistent with that of Ng,26 who found 
that self-esteem for women living with SLE was negatively 
impacted by changes in body appearance, such as weight 
gain and hair loss.
When responding to the SLENQ, the sample overwhelm-
ingly reported that the highest general cause of depressive and 
anxious feelings was changes in appearance and   limitations in 
physical abilities due to SLE, primarily muscle and joint pain. 
The more chronic the symptoms, the more likely that   feelings 
of depression would arise. The more frequent the flares, 
the more intense the emotional distress. These   correlations 
between symptomatology and emotional   distress are consis-
tent with the findings of other psychosocial researchers in this 
area, and our sample represents a larger and more ethnically 
diverse sample.27
Learning that African-Americans and Hispanics report a 
higher vulnerability for SLE-related depression and anxiety, 
as well as poorer socioeconomic coping than their White and 
Asian counterparts, is an important finding. This should alert 
the health care team to integrate social supports into treatment 
for this population and inform those who develop program 
service delivery for this population. This finding is consistent 
with those of other studies reporting health disparities among 
race and class, ie, the larger burden of disease that Hispanics 
and African-Americans carry, as well as higher mortality 
and complication rates.28,29 From our data, it is unclear what 
role language or cultural barriers play in the higher rates 
of depression reported by Hispanics. This can be further 
clarified in future research. While all SLE patients should be 
assessed comprehensively, Hispanic and   African-American 
women may require more psychosocial resources and sup-
port, and every effort has to be made to provide culturally 
competent assessment and intervention.30,31 It is critical to 
appreciate the psychological impact of this illness and the 
negative side effects of various medical regimens and how 
these may impact mood changes, and as Moses and Ng 
found, feelings of low-self-esteem, capacity for self-care, and 
medication compliance.12,24–26 The Hispanic cohort reported 
the most emotional distress and reported facing the most 
  socioeconomic distress.
The data also found that the more one perceives control 
over the illness and the more education one has, the less 
likely one is to report feeling depressed or anxious about 
SLE challenges. This is an important finding because there 
have been no other psychosocial studies which were able to 
confirm this important relationship. A related study demon-
strated that SLE patients with lower levels of education tend 
to be more anxious, as well as less compliant with visiting 
their physician.27,28 Some possible suppositions about this 
correlation are that the more educated one is, the better one 
may be able to understand SLE, and the more resources one 
may have to cope more adaptively.3,4
Identifying that those affected by muscle pain and hair 
loss tend to be more vulnerable to feelings of depression 
and anxiety is significant for treating physicians, as well as 
for individual and group counselors. One has to consider 
the dynamic interplay of the disease manifestations and the Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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  emotional state, because muscle pain and hair loss could 
influence depression and anxiety. The converse is also 
  possible, ie, that depression and anxiety could result in both 
muscle pain and hair loss. Individual and group counseling 
with SLE patients should allow for exploration and expres-
sion of feelings about these specific SLE manifestations 
and the range of potentially troubling side effects from SLE 
medications.29 Clinical initiatives and program develop-
ment should emphasize patient education and advocacy 
because this has been found to be a mitigating factor in both 
  depression and anxiety for this population.31
The great majority of SLE patients on medication expe-
rience a wide range of side effects, the most prominent of 
which is hair loss and weight gain, and yet when asked what 
they wanted from a new medication, the answer was “fewer 
flares”. It is difficult to be definitive regarding certain side 
effects because some patients may interpret an SLE symptom 
as a side effect, eg, they may report that Plaquenil® is causing 
hair loss, but it is also possible that increased SLE activity 
is the culprit. For many, if they are on steroids, they have 
active disease, which has its own sequelae.
The prevalence of emotional distress for this popula-
tion would indicate that intake, assessment, and treatment 
include inquiry into the psychosocial impact of the illness, 
with a focus on depression, anxiety, and socioeconomic 
coping. Assessment should pay particular attention to how 
a patient has been coping with any changes in appearances 
and limitations due to SLE, as well as the emotional impact 
of any side effects they may be experiencing. Any adjust-
ments that can be made to medical regimens with negative 
side effects should be considered wherever possible. The 
issue of control for an SLE patient may include information, 
patient   education, and advocacy, as well as emphasizing 
self-actualization for patients in the use of their resources 
and psychosocial support.12 SLE patients manifesting signs 
of depressive thinking, anxiety, and difficulty in socioeco-
nomic coping, should be referred to social workers who 
should employ active therapeutic approaches, such as crisis 
intervention and task-centered counseling, to combat the 
unpredictable nature of SLE.32
Identifying and confirming that feelings of depression and 
anxiety occur at significant rates for those living with SLE 
is critical. Those working in health care should be alerted to 
which SLE populations are at higher risk, ie, Hispanic and 
African-American women, and which manifestations trigger 
the greatest likelihood of feeling depressed and anxious, ie, 
changes in appearance due to SLE, limitations in physical 
abilities, joint pain, and weight gain.
Depression and anxiety are broad terms that can reflect 
very different levels of intensity and frequency for each 
patient. The SLENQ should be accompanied by the Iverson 
Depression scale in future research in order to gain more 
precision for health care treatment.33 The overriding study 
question for future research is – how does the depressed state 
influence disease activity, disease management, and psycho-
social experience of the disease? In addition, further studies 
should examine SLE patients longitudinally to determine 
how patients cope adaptively and what strengths (internal 
and external) aid in the resilience of patients coping with 
this chronic disease over time.
Conclusion
This study explored self-reported states of depression and 
anxiety in SLE patients using the SLENQ instrument, as 
well as the relationship between perceived sense of control 
and states of depression and anxiety for the SLE patient. 
Key findings demonstrated that individuals with SLE were 
more likely to experience depression and anxiety when there 
were changes in body appearance due to SLE, and to experi-
ence limitations in physical abilities due to SLE, primarily 
due to muscle and joint pain. The higher the perceived 
sense of control over SLE, the less likely respondents were 
to report feeling depressed and anxious. African-American 
and Hispanic SLE patients reported a higher level of unmet 
psychological needs than did their other ethnic counterparts. 
Weight gain and hair loss were the most likely medication 
side effects, and the most likely to trigger SLE-related 
  depression and anxiety.
Whether the health care provider is the treating physi-
cian, nurse, social worker, or any other member of a health 
care team, it is essential to assess this population for how 
emotional states may impact disease activity, self-care, and 
medication compliance. The SLENQ proved a reliable, valid, 
and comprehensive assessment tool for identifying psycho-
social needs related to SLE. The health care team treating 
this population should be alert to the potential psychosocial 
impact of SLE, such as depression and anxiety. Health care 
providers should include comprehensive biopsychosocial 
screening and assessment wherever possible, and make refer-
rals where needed in order to address the emotional sequelae 
of living with SLE.
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